Alvotech and Fuji Pharma Extends Agreement for the Commercialization of Four Biosimilars in Japan

December 14, 2020 Auto Bot Agreement, Alvotech, Biosimilar, Biosimilars, Commercialization, Japan 0

Shots:

  • The agreement strengthens the ongoing collaboration b/w the companies signed in 2018 to commercialize Alvotech’s biosimilar portfolio in Japan
  • Fuji Pharma currently owns a minority stake in Alvotech and now can enter new therapeutic areas following the agreement
  • With the extension of the agreement, Fuji Pharma has a leading biosimilar pipeline in Japan. Fuji Pharma will use its strong local expertise in commercializing Alvotech’s portfolio in Japan

Click here ­to­ read full press release/ article | Ref: Alvotech | Image: Alvotech

The post Alvotech and Fuji Pharma Extends Agreement for the Commercialization of Four Biosimilars in Japan first appeared on PharmaShots.